Business Standard

Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21

Dr Lal Pathlabs, laboratory, tests, Pathology
Premium

SI Reporter Mumbai
Shares of Dr Lal Pathlabs hit 52-week low of Rs 2,047.70 and slipped 6 per cent on the BSE in Wednesday’s intra-day trade. The decline comes after the company posted 14 percent dip year on year (YoY) in consolidated profit after tax (PAT) to Rs 72.9 crore in March quarter (Q4FY22). The company, a leading diagnostic and related healthcare service provider, had posted profit of Rs 85.1 crore in the same quarter last fiscal.

The stock breached its previous low of Rs 2,151.05 that it had touched on Monday, May 16, 2022. In the past one month, the stock

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in